Quality of Life and Capsaicin Sensitivity in Patients with Airway Symptoms Induced by Chemicals and Scents: A Longitudinal Study

Ewa Ternesten-Hasseus, Olle Löwhagen, and Eva Millqvist

Asthma and Allergy Research Group, Department of Respiratory Medicine and Allergology, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden

OBJECTIVE: It is common in asthma and allergy clinics to see patients presenting with upper and lower airway symptoms that are induced by chemicals and scents and not explained by allergic or asthmatic reactions. Previous studies have shown that these patients often have increased cough sensitivity to inhaled capsaicin; such sensitivity is known to reflect the airway sensory reactivity. The aim of this study was to evaluate the duration of symptoms induced by chemicals and scents and to measure health-related quality of life (HRQL) in patients with chemically induced airway symptoms. We also wished to determine and compare repeatability of the cough response to capsaicin inhalation, and to evaluate the patients’ airway sensory reactivity in a long-term perspective.

PARTICIPANTS: Seventeen patients with a history of at least 12 months of airway symptoms induced by chemicals and scents were followed over 5 years with repeated questionnaires, measurements of HRQL, and capsaicin inhalation tests.

RESULTS: The symptoms persisted and did not change significantly over time, and the patients had a reduced HRQL that did not change during the 5-year period. The capsaicin sensitivity was increased at the start of the study, the cough sensitivity was long-lasting, and the repeatability of the capsaicin inhalation test was considered to be good in a long-term perspective.

CONCLUSIONS: Upper and lower airway symptoms induced by chemicals and scents represent an entity of chronic diseases, different from asthma or chronic obstructive pulmonary disease, with persistent symptoms, a reduced HRQL, and unchanged sensory hyperreactivity.

KEY WORDS: asthma, capsaicin, cough, environment, health-related quality of life, multiple chemical sensitivity, sensory hyperreactivity. Environ Health Perspect 115:425–429 (2007). doi:10.1289/ehp.9624 available via http://dx.doi.org/ [Online 19 December 2006]
symptoms induced by chemicals and scents; b) determine and compare repeatability of the cough response to capsaicin inhalation; and c) evaluate the patients’ sensory reactivity in a long-term perspective.

**Materials and Methods**

**Patients.** The study group included 17 patients (13 women and 4 men; median age of 48 years) who were consecutively selected over a period of about 9 months, when they were referred to our outpatient asthma and allergy clinic because of symptoms suggestive of asthma or allergies accompanied by treatment failure. They were screened using a questionnaire on airway symptoms and symptoms in response to chemicals and scents. The patients had at least a 1 year (median 9 years) history of upper and lower airway symptoms induced by chemicals and scents. Within the last 3 years, all patients had had a skin prick test (SPT) with a standard panel of 10 allergen sources common to Sweden. The SPT was negative for all of the patients except for two who had a minor positive reaction to mugwort, which was regarded as being without clinical importance. The methacholine test, administered according to the method described by Lowhagen (1984), was negative for all patients. None of the patients demonstrated spirometric reversibility or variability in pulmonary function. Ten of the patients had never smoked, six had ceased smoking > 2 years before the study began, and one had ceased smoking 2 months previously. All participants except one were tested in a standardized way with the 1-butanol test and the Scandinavian Odor-Identification Test (SOIT) (Cain et al. 1988; Nordin et al. 1998). All had a normal sense of smell according to the SOIT, although three had hyposmia (a reduced ability to smell and to detect odors) according to the 1-butanol test. Demographic data of the patients are presented in Table 1.

Informed consent was obtained from all patients. The study was approved by the Regional Ethical Review Board of Göteborg, Sweden.

**Study design.** The patients were followed over a period of approximately 5 years. The patients saw their ordinary physician during the follow-up time, and we did not interfere in their treatment. During the first year, patients visited the clinic four times for a capsaicin inhalation test. They then visited the clinic approximately once a year during the following 4 years. At each study visit, the patients underwent a capsaicin inhalation test (eight capsaicin tests in total). Before the first appointment, and once per year thereafter, the patients answered a local questionnaire and their HRQL was evaluated (six times in total). All of the questionnaires were sent by mail, completed at home, and mailed back.

**Questionnaires.** At the beginning of the study, the patients answered a local questionnaire about symptoms and triggering factors for symptoms. They were asked to score symptoms that they had experienced over the previous year on a scale of 0–3 (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; and 3 = severe symptoms). Fourteen symptoms were analyzed: heavy breathing, difficulty getting air, chest weight, cough, phlegm, throat irritation, hoarseness, nasal blockage, rhinorrhea, eye irritation, sweating, headache, dizziness, and fatigue. To allow test–retest evaluation of the symptom score questionnaire, the patients completed this questionnaire twice at the beginning of the study. The patients were also asked about their working capacity and the medication they used at the start of the study and then once each year.

**Health-related quality of life.** HRQL was assessed using the NHP questionnaire, a generic, self-administered instrument for measuring various aspects of HRQL (Hunt and McEwen 1980). The questionnaire has been shown to have both high validity and high reliability (Hunt et al. 1981, 1984; Wiklund et al. 1988). It consists of two parts. Part I contains 38 items covering six aspects of HRQL, concerning the domains of physical mobility, pain, energy, sleep, social isolation, and emotional reactions. The response alternatives for each item are “yes” and “no,” depending on whether that item fits the individual’s current situation. The possible score for each dimension ranges from zero (no problems at all) to 100 (presence of all problems within the area). The weighting procedure is based on Thurstone’s “paired comparison” method (McKenna et al. 1981). Part II of the NHP contains seven questions, again with yes/no alternatives, concerning the impact of health problems on the individual’s social functioning in terms of paid employment, housework, social life, family life, sex life, hobbies, and holidays. For part II, the proportions of positive answers to each of the seven questions are calculated separately and compared with the reference values. The patients were asked to

---

**Table 1. Demographic data for 17 patients with airway symptoms induced by chemicals and scents.**

| Patient no. | Sex   | Age (years) | Duration of symptoms (years) | Baseline FEV₁ (percent predicted) | Profession                        |
|------------|-------|-------------|------------------------------|----------------------------------|-----------------------------------|
| 1          | F     | 45          | 3                            | 95                               | Secretary/unemployed              |
| 2          | M     | 42          | 2                            | 87                               | Clerk                             |
| 3          | F     | 60          | 21                           | 91                               | Disability pension                |
| 4          | F     | 52          | 15                           | 77                               | Nurse/periodically sick-listed    |
| 5          | F     | 58          | 10                           | 108                              | Teacher/periodically sick-listed  |
| 6          | M     | 56          | 10                           | 83                               | Clerk                             |
| 7          | M     | 48          | 8                            | 88                               | Priest/periodically sick-listed   |
| 8          | F     | 52          | 3                            | 120                              | Nurse/periodically sick-listed    |
| 9          | F     | 48          | 11                           | 109                              | Occupational therapist’s assistant|
| 10         | F     | 37          | 4                            | 95                               | Clerk                             |
| 11         | F     | 30          | 10                           | 121                              | Statistician                      |
| 12         | F     | 31          | 15                           | 131                              | Artist/unemployed                 |
| 13         | F     | 47          | 2                            | 112                              | Postman/periodically sick-listed  |
| 14         | M     | 61          | 5                            | 91                               | Disability pension                |
| 15         | F     | 53          | 1                            | 106                              | Clerk                             |
| 16         | F     | 38          | 25                           | 96                               | Salesman                          |
| 17         | F     | 27          | 2                            | 78                               | Engineer/periodically sick-listed |

**Abbreviations:** F, female; FEV₁, forced expiratory volume in 1 sec; M, male.

---

**Table 2. Number of patients reporting trigger factors, symptoms, and medication at the first and last visits in the study.**

| Trigger factors     | No. of patients | Symptoms reported | No. of patients taking medication | Medication | No. of patients | First visit | Last visit |
|---------------------|-----------------|-------------------|----------------------------------|------------|----------------|-------------|------------|
| Flower scents       | 14              | 15                | 15                               | Inhalation steroids | 1              | 1           |            |
| Car exhaust fumes   | 13              | 11                | 11                               | Nasal steroids | 6              | 1           |            |
| Perfume             | 16              | 14                | 14                               | Oral steroids | 2              | 0           |            |
| Cigarette smoke     | 16              | 17                | 17                               | Antihistamines | 2              | 3           |            |
| Colored paints      | 16              | 12                | 12                               | β₂-Agonists | 6              | 2           |            |
| Exercise            | 15              | 12                | 12                               | Antidepressant medication | 2          | 2           |            |
| Cold air            | 13              | 13                | 13                               | Hoarseness | 10             | 10          |            |
|                     |                 |                   |                                  | Nasal blockage | 10             | 10          |            |
|                     |                 |                   |                                  | Rhinorrhea | 10             | 10          |            |
|                     |                 |                   |                                  | Eye irritation | 15            | 15          |            |
|                     |                 |                   |                                  | Sweating    | 8              | 8           |            |
|                     |                 |                   |                                  | Headache    | 11             | 11          |            |
|                     |                 |                   |                                  | Dizziness   | 3              | 3           |            |
|                     |                 |                   |                                  | Fatigue     | 13             | 13          |            |
answer the questions according to their actual current condition.

Reference values for NHP. We used norm and reference values distributed by age and sex for parts I and II of the NHP. These values are based on data from larger populations that are currently used in family practice (Hunt and Wiklund 1987).

Capsaicin inhalation. We prepared a stock solution of capsaicin (Sigma-Aldrich Sweden AB, Stockholm, Sweden; 1 mmol/L in ethanol (99.5%)). We then diluted the stock solution with 0.9% saline, containing 1% ethanol by volume, to prepare aqueous provocation solutions of 0.4, 2, and 10 µmol/L. The provocation solutions were prepared regularly and stored frozen. A capsaicin aqueous solution of 100 µmol/L retains total stability after 3 months of storage in a freezer (Ternesten-Hasséus et al. 2002b).

Capsaicin was nebulized (Pari Boy 36, type 37.0130; Paulirzau Pari-Werk GmbH, Starnberg, Germany) and inhaled through a mouthpiece (Pari Inhalierboy, no. 36.75) by tidal volume breathing; a nose clip was not used. Saline (1 mL) and the three increasing concentrations of capsaicin (0.4, 2, and 10 µmol/L) in a 1-mL solution were inhaled to completion, or for a maximum of 6 min, in order to induce coughing; this was followed by a 4-min rest period. The total number of evoked coughs was counted for 10 min from the onset of each inhaled capsaicin concentration. Cough registration was performed by the same counter using a tape recorder. The total duration of each capsaicin inhalation test was approximately 45 min. On the first three occasions, no limit was set on the number of coughs. In the following tests, however, out of consideration for the patients, provocation was stopped if one dose of capsaicin provoked > 70 coughs. The forced expiratory volume in 1 sec (FEV₁) was measured using a calibrated spirometer (Vitalograph, Buckingham, UK) before and after the inhalation test, and the highest of three values was recorded.

Capsaicin inhalation was not performed in patients who had experienced respiratory infections within 1 month before scheduled testing. All medication was withheld for at least 4 hr, and antihistamines were withheld for at least 5 days before the inhalation tests.

Statistical analysis. We used the Wilcoxon signed-rank test for paired data and the Mann-Whitney U-test for nonpaired data. The test–retest reliability of the symptom score questionnaire was determined using Spearman’s rank correlation coefficient. For part I of the NHP, we used Friedman’s test to compare repeated measurements. Fisher’s exact test was used in part II for nonpaired data, and Cochran’s Q-test was used in part II for repeated measurements.

The repeatability of the capsaicin inhalation test was determined using the method of Bland and Altman (1986). In this method, repeatability is analyzed by taking repeated measurements on a series of subjects. The result is examined using a simple plot showing the results of one measurement against those of the other measurement for each subject, and a plot of the difference between the measurements against their mean. The coefficient of reproducibility is calculated as 2 standard deviations (SDs) from the mean of the difference in coughing.

A probability (p) value < 0.05 was considered statistically significant.

Results

Each of the 17 subjects visited the clinic four times during the first year. Three patients declined to perform the capsaicin provocation in year 3, and four patients declined in years 4 and 5. The reasons for drop out were recurrent airway infections (subjects 1, 8, and 13), moving to another city (subject 7), fear of experiencing prolonged airway symptoms due to the provocation (subject 12), and pregnancy or expected pregnancy (subjects 11 and 17).

The median value of FEV₁ was 96% of that predicted before the first capsaicin inhalation test, and no significant difference was found after the capsaicin provocations. During the 5-year follow-up, we found no significant changes in the median values of FEV₁ compared with the initial baseline values.

Questionnaires. Table 2 presents patient data about medications used at the first and the last visit of the study, reported symptoms at the first appointment in the study, and factors triggering these symptoms. During the 5-year follow-up, 3 patients were granted a disability pension, whereas 9 patients had problems with their working capacity because of their sensitivity to chemical agents; 6 of these patients were periodically on sick leave because of their symptoms, alone or together with other conditions (muscular problems in 3 patients). There were some individual variations in the symptom scores, but in the group as a whole, the patients reported persistent symptoms without statistically significant changes between the first and last visit during the study (Table 3).

The test–retest reliability of the symptom score questionnaire was high (r₁ = 0.77; p < 0.01) indicating good reliability for the questionnaire.

Health-related quality of life. In the primary evaluation for part I of the NHP, patients had a significantly higher (p < 0.05) score for social isolation than the reference group. There were no statistically significant differences compared with the reference group in the other five dimensions (physical mobility, pain, energy, sleep, and emotional reactions).

Part II of the NHP is presented in Figure 1 as a percentage of positive responses. The patients demonstrated significantly more problems than the reference group for five of the seven questions: paid employment (p < 0.05), housework (p < 0.05), social life (p < 0.01), hobbies (p < 0.01), and holidays (p < 0.05). Over the 4-year period the patients demonstrated no significant changes in any parts of the NHP compared with their initial evaluation.

Capsaicin inhalation. We counted the number of coughs by listening to the tape

Table 3. Severity (mean ± SD) of 14 symptoms in 17 patients in the first and last visits of the study, based on a score of 0–3.

| Symptom                  | First visit | Last visit |
|-------------------------|------------|-----------|
| Heavy breathing          | 1.35 ± 1.11| 1.12 ± 0.78|
| Difficulty getting air   | 0.76 ± 0.90| 0.59 ± 0.79|
| Chest weight             | 1.17 ± 1.18| 0.82 ± 1.01|
| Cough                    | 1.52 ± 1.12| 1.70 ± 0.98|
| Phlegm                   | 1.18 ± 1.07| 1.29 ± 1.07|
| Throat irritation         | 1.09 ± 0.83| 1.09 ± 0.98|
| Hoarseness               | 1.00 ± 1.27| 0.70 ± 1.04|
| Nasal blockage           | 1.18 ± 1.33| 1.23 ± 1.15|
| Rhinorrhea               | 1.24 ± 1.03| 0.89 ± 0.92|
| Eye irritation            | 1.24 ± 1.09| 0.89 ± 0.99|
| Sweating                 | 0.88 ± 0.99| 0.89 ± 0.99|
| Headache                 | 1.18 ± 1.07| 1.47 ± 1.23|
| Dizziness                | 0.29 ± 0.77| 0.47 ± 0.72|
| Fatigue                  | 1.64 ± 1.17| 1.53 ± 1.28|

Figure 1. Percentage of positive responses reflecting problems in daily activity at the first appointment in year 1 in part II of the NHP for 17 patients and reference values. NS, not significant.

* p < 0.05  ** p < 0.01.
recordings. The patients coughed dose-dependently during the capsaicin provocations (Figure 2). Of the 17 patients, 15 had increased capsaicin cough sensitivity and reached the threshold set for the diagnosis of SHR according to Johansson et al. (2002). The inhalation was stopped for approximately 8 patients during each capsaicin inhalation test because they responded to one dose with > 70 coughs. Because there was no cough limit for the initial three provocations in the first year of the study, these results were not compared with the others. On each test occasion, many patients reached the cough limit at the highest dose of inhaled capsaicin (10 μmol/L); therefore, only results from the doses of 0.4 and 2 μmol/L are presented. We observed no significant differences between the numbers of coughs during the fourth provocation of the first year and the provocations of the second and third years. There was a significant decrease in the number of coughs between the fourth provocation of the first year and the provocations of the fourth and fifth years ($p < 0.05$).

We calculated repeatability using a capsaicin concentration of 2 μmol/L. We compared the very first capsaicin provocation with the second provocation of the first year; the interval between these was about 3 months. The number of coughs after inhalation of 2 μmol/L capsaicin correlated significantly between these two provocation events ($r = 0.78; p < 0.001$) (Figure 3A). The SD from the mean difference between the 17 pairs of repeated measurements among the patients was 24 coughs for the 2-μmol/L capsaicin dose. The coefficient of repeatability was thus calculated to be 48 coughs (Figure 3B).

To evaluate the patients’ sensory reactivity in a longer perspective, we examined the repeatability of the capsaicin inhalation test using the same technique. We analyzed the two appointments in which the largest number ($n = 15$) of the same participants attended: the last provocation of the first year and the provocation of the third year. The number of coughs after inhalation of 2 μmol/L capsaicin correlated significantly between these two provocation occasions ($r = 0.76; p < 0.001$) (Figure 4A). The SD from the mean difference between the 15 pairs of repeated measurements among the patients was 21.5 coughs for the 2-μmol/L capsaicin dose. The coefficient of repeatability was thus calculated to be 43 coughs (Figure 4B).

**Discussion**

In this 5-year study, we followed 17 patients with previously medically unexplained airway symptoms induced by chemicals and scents. These symptoms are often misdiagnosed as asthma or allergy, but they can be recognized using a capsaicin inhalation cough test (Johansson et al. 2002; Millqvist et al. 1998). According to this test, the majority of the patients in the present study (15 of 17) could be diagnosed with SHR. None of the patients recovered from their symptoms, and none developed asthma, chronic obstructive pulmonary disease, or any other known lung disease. After 5 years, brief exposure to substances such as perfume, colored paints, or cigarette smoke could still evoke symptoms, which had a long-term negative impact on the daily life of the patients. The patients reported long-lasting impairment in five of the seven activities in part II of the NHP (paid employment, housework, social life, hobbies, and holidays) compared with a population sample. They also reported significantly higher scores (more difficulties) for social isolation in part I of the NHP.

None of the patients in the present study demonstrated any serious adverse reaction or bronchoconstriction after the capsaicin
inhalation test. In a recent review, Dicpinigaitis and Alva (2005) concluded capsaicin inhalation to be a safe research tool, with no serious adverse reactions reported over the past two decades. In two other studies with long-term occupational exposure to capsaicin, no demonstrable change in pulmonary function was seen (Blanc et al. 1991; Lankatilake and Uragoda 1993). Inhalation of three increments of capsaicin contains a total of 0.00377 g capsaicin, if the subject is able to inhale all three concentrations. This can be compared to a meal containing 100 g of fresh chili peppers, which would contain 0.1–1 g pure capsaicin. In some countries, consumption can be as high as approximately 3 g pure capsaicin per day (Gövdanarajan 1986). From this perspective, it seems unlikely that the capsaicin inhalation test could pose any risk to the patients.

Capsaicin-induced cough can, to a certain extent, be voluntarily suppressed or enhanced (Hutchings et al. 1993). Some individuals can avoid coughing when inhaling capsaicin, but the cough reflex becomes irrevocable with increasing concentrations. In previous studies, inhalation of capsaicin induced a dose-dependent and reproducible cough in patients with SHR and healthy controls, when the capsaicin provocations were performed in a double-blind randomized fashion (Millqvist 2000; Ternesten-Hasseus et al. 2002a, 2006). With regard to the good long-term reproducibility, it seems unlikely that the patients could have intentionally influenced the outcome of the cough provocations. Although we found some individual changes in capsaicin cough sensitivity, the sensory reactivity among the patients was increased and long-standing.

Medically unexplained physical symptoms are common in clinical care and within the general population; examples include chronic fatigue syndrome, fibromyalgia, MCS, idiosyncratic environmental intolerances, somatoform disorders, and “Gulf War syndrome.” These symptoms are associated with extensive morbidity and have a significant impact on everyday functions (Baldwin et al. 1997; Black et al. 1999; Kipen et al. 1995; Kreutzer et al. 1999; Meggs et al. 1996). The association of these symptoms and environmental exposure is often sharply debated, as is the distinction between the various syndromes themselves (Kipen and Fiedler 2002; Richardson and Engel 2004; Wiesmuller et al. 2003). However, in spite of the uncertainties in the evaluation of environmental syndromes, physicians have a duty to deal with the symptoms of those affected.

In conclusion, airway symptoms induced by chemicals and scents can be regarded as a chronic condition and may represent an entity of chronic diseases, with persistent symptoms, a reduced HRQL, and unchanged long-lasting sensory hyperreactivity. The repeatability for the capsaicin inhalation test is good in a short-term and long-term perspective. Although the capsaicin inhalation test was valuable for diagnosing these patients, the cause of their symptoms remains obscure, and there is currently no effective treatment; this emphasizes the need for future parapsychologic research.

References

American Academy of Allergy, Asthma and Immunology Board of Directors. 1999. Idiopathic environmental intolerances. J Allergy Clin Immunol 103(1): Pt 1:38–40.
Baldwin CM, Bell IR, O’Rourke MK, Lebowitz MD. 1997. The association of respiratory problems in a community sample with self-reported chemical intolerance. Eur J Epidemiol 13(5):547–552.
Black DW, Doebbeling BN, Voelker MD, Clarke WR, Wolsflon RF, Barrett DH, et al. 1999. Quality of life and health-care utilization in a population-based sample of military personnel reporting multiple chemical sensivities. J Occup Environ Med 41(8):629–633.
Pia Blou, P Liu, D Joaruz, C Boushey HA. 1991. Cough in hot pepper workers. Chest 99(1):27–32.
Blanc JM, Alteme DG. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307–310.
Cain WS, Gent JF, Goodspeed RB, Leonard G. 1988. Evaluation of olfactory dysfunction in the Connecticut Chemosensory Clinical Research Center. Laryngoscope 98(1):83–88.
Cullen MR. 1987. The worker with multiple chemical sensivities: an overview. Occup Med 2(4):655–661.
Dicpinigaitis PV. 2003. Short- and long-term reproducibility of capsaicin cough challenge testing. Pulm Pharmacol Ther 16(1):61–65.
Dicpinigaitis PV, Alva RV. 2005. Safety of capsaicin cough challenge testing. Chest 128(1):196–202.
Fuller R, Dixon C, Barnes P. 1985. Bronchoconstrictor response to inhaled capsaicin in humans. J Appl Physiol 58:1080–1084.
Govindarajan VS. 1986. Capsicum—production, technology, chemistry, and quality—Part II. Processed products, standards, world production and trade. Crit Rev Food Sci Nutr 23(3):207–288.
Graveling RA, Pilkington A, George JP, Butler MP, Tannahill SN. 1999. Changes in levels of nerve growth factor in nasal secretions of controls and patients with non-specific bronchial hyperreactivity. Eur J Respir Dis 102:98–105.
Hunt SM, Wiklund I. 1987. Cross-cultural variation in the weighting of health statements: a comparision of English and Swedish valuations. Health Policy 8:227–235.
Hunt S, McEwen J, McKenna S. 1984. Perceived health. Age and sex norms in a community. J Epidemiol Commun Health 38:165–170.
Hunt S, McEwen J. 1980. The development of a subjective health indicator. Social Health Illness 2:231–246. PMID: 10298135.
Hunt SM, McKenna SP, Williams J. 1981. Reliability of a population survey tool for measuring perceived health problems: a study of patients with osteoarthrosis. J Epidemiol Community Health 36:156–160.
Hunt SM, Wiklund I. 1987. Cross-cultural variation in the weighting of health statements: a comparision of English and Swedish valuations. Health Policy 8:227–235. PubMed.gov: 16(1):61–65.
Kipen HM, McEwen J. 1981. Weighting the serious-ness of perceived health problems using Thurstone’s method of paired comparisons. Int J Epidemiol 20:93–97.
Meggs JW, Dunn KA, Bloch RM, Goodman PE, Davidoff AL. 1996. Prevalence and nature of allergy and chemical sensitivity in a general population. Arch Environ Health 51(4):275–281.
Midgren B, Hansson L, Karlsson J-A, Simonsson BG, Persson CGA. 1992. Capsaicin-induced cough in humans. Am Rev Respir Dis 146:342–347.
Millqvist E. 2000. Cough provocation with capsaicin is an objective way to test sensory hyperreactivity in patients with asthma-like symptoms. Allergy 55(6):546–550.
Millqvist E, Bende M, Lowhagen O. 1998. Capsaicin cough provocation—a possible mechanism underlying cough and asthma-like symptoms. Allergy 53(1):128–1212.
Millqvist E, Lowhagen O, Bende M. 2000. Quality of life and capsaicin sensitivity in patients with sensory airway hyperreactivity. Allergy 55(6):540–545.
Millqvist E, Ternesten-Hasseus E, Stahl A, Bende M. 2005. Changes in levels of nerve growth factor in nasal secretions after capsaicin inhalation in patients with airway symptoms from scents and chemicals. Environ Health Perspect 113:849–852.
Morice AH, Geppetti P. 2004. Cough: The type I vanilloid receptor: a sensory receptor for cough. Thorax 59(3):257–258.
Nogami H, Odaizama H, Shoji S, Shimoda T, Nishima S. 2004. Capsaicin provocation test as a diagnostic method for determining multiple chemical sensitivity. Allergology Int 53(2):153–159(195).
Nordin S, Brämersson A, Liden E, Bende M. 1998. The Scandinavian Odor-Identification Test: development, reliability, validity and normative data. Acta Otolaryngol (Stockh) 118:226–234.
Richardson RD, Engel CC Jr. 2004. Evaluation and management of medically unexplained physical symptoms. Neurology 101(15):1–10.
Ringsberg KC, Wicklund I, Willenheimer L. 1990. Education of adult patients at an ‘asthma school’: effects on need for nursing and quality of life. J Eur Respir Dis 3:33–37.
Ternesten-Hasseus E, Bende M, Millqvist E. 2002a. Increased capsaicin cough sensitivity in patients with multiple chemical sensivities. J Occup Environ Med 44(1):1102–1107.
Ternesten-Hasseus E, Farbrot A, Lowhagen O, Millqvist E. 2002b. Sensitivity to methacholine and capsaicin in patients with unclear respiratory symptoms. Allergy 57(6):501–507.
Ternesten-Hasseus E, Johansson K, Lowhagen O, Millqvist E. 2006. Inhalation method determines outcome of capsaicin inhalation in patients with chronic cough due to sensory hyperreactivity. Pulm Pharmacol Ther 19(3):172–178.
Tsukino M, Nishimura K, Ikeda A, Koyama H, Mishima M, Izumi T. 1996. Physiologic factors that determine the health-related quality of life in patients with COPD. Chest 110(4):896–903.
Wiemer GA, Ebel H, Hornberg C, Kowan O, Friel J. 2003. Are syndromes in environmental medicine variants of somatoform disorders? Med Hypoth 59:709–715.
Wicklund I, Comerford M, Dimenäs E. 1991. The relationship between exercise tolerance and quality of life in angina pectoris. Clin Cardiol 14:204–208.
Wicklund I, Romanus B, Hunt S. 1997. Self-assessed disability in patients with arthritis of the hip joint. Reliability of the Swedish version of the Nottingham Health Profile. Int Disabil Stud 19:105–109.